Raymond DuBois Named Dean of MUSC College Of Medicine

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

RAYMOND DUBOIS was named the next dean of The Medical University of South Carolina College of Medicine. DuBois will assume his new role effective March 1, 2016, with an academic appointment as professor while also holding an appointment in the Hollings Cancer Center.

DuBois currently serves as executive director of the Biodesign Institute at Arizona State University. Prior to his appointment at Arizona State, DuBois was provost and executive vice president at MD Anderson Cancer Center, overseeing all research, education, training and faculty development.

Prior to joining MD Anderson, DuBois was a professor at Vanderbilt University Medical Center in the departments of Internal Medicine and Cancer Biology, director of the Vanderbilt-Ingram Cancer Center, and prior to that, chief of Gastroenterology, Hepatology and Nutrition.

DuBois has served in many leadership roles, among them as past president of the American Association for Cancer Research and the International Society for Gastrointestinal Cancer. DuBois will continue his leadership in cancer discovery through his ongoing research, engagement with the NCI, and through partnership with the Hollings Cancer Center. He also currently serves on the Executive Management Committee for the Stand Up to Cancer Foundation, and is the president and chair of the AACR Foundation Board.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login